- Report
- June 2024
- 66 Pages
Europe
From €5691EUR$5,995USD£4,801GBP
- Report
- June 2024
- 69 Pages
Asia Pacific
From €5691EUR$5,995USD£4,801GBP
- Report
- June 2024
- 30 Pages
United States
From €4742EUR$4,995USD£4,000GBP
- Report
- June 2024
- 51 Pages
China
From €522EUR$550USD£440GBP
€1044EUR$1,100USD£881GBP
- Report
- February 2021
- 144 Pages
Global
From €1305EUR$1,375USD£1,101GBP
€2611EUR$2,750USD£2,202GBP
- Report
- March 2020
- 82 Pages
Global
From €854EUR$900USD£721GBP
- Report
- September 2023
- 90 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- October 2021
- 75 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- November 2023
- 250 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- December 2024
- 88 Pages
Egypt
From €3323EUR$3,500USD£2,803GBP
From €3323EUR$3,500USD£2,803GBP
- Report
- October 2023
- 88 Pages
Malaysia
From €3323EUR$3,500USD£2,803GBP
- Report
- October 2023
- 127 Pages
North America
From €3797EUR$4,000USD£3,203GBP
- Report
- November 2023
- 89 Pages
France
From €3323EUR$3,500USD£2,803GBP
- Report
- February 2024
- 111 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- February 2024
- 110 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- April 2023
- 110 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- July 2022
- 100 Pages
Global
From €2611EUR$2,750USD£2,202GBP
- Report
- January 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- January 2024
- 83 Pages
From €3275EUR$3,450USD£2,763GBP

The aortic valve replacement market is a segment within the broader field of cardiovascular devices that focuses on treatments for aortic valve disorders, such as aortic stenosis or aortic insufficiency. This market includes the development, manufacturing, and sale of prosthetic aortic valves intended to replace diseased or malfunctioning native valves in patients. Two primary types of valves are used in aortic valve replacements: mechanical valves, which are made from durable materials like titanium or carbon, and biological valves, which are made from tissue derived from animal sources or donated human hearts. With advancements in medical technology, the market has expanded to include less invasive procedures like transcatheter aortic valve replacement (TAVR), which allows for the placement of a new valve without the need for open-heart surgery. This market segment is driven by an aging population, the rising prevalence of heart valve diseases, and continued innovation in valve technologies and surgical techniques.
Among the companies that are key players in the aortic valve replacement market, some include Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, and LivaNova. These companies are known for their contributions to the development of both transcatheter and surgical valve replacement technologies and their consistent efforts to improve patient outcomes through advancements in cardiovascular device engineering. Show Less Read more